Loading...
XKRX
302440
Market cap2.67bUSD
Jul 25, Last price  
47,200.00KRW
1D
-0.53%
1Q
16.69%
IPO
-71.65%
Name

SK Bioscience Co Ltd

Chart & Performance

D1W1MN
P/E
P/S
13.83
EPS
Div Yield, %
Shrs. gr., 5y
0.09%
Rev. gr., 5y
7.78%
Revenues
267.55b
-27.59%
88,173,588,380183,937,702,390225,610,784,860929,000,929,910456,725,871,190369,505,555,850267,545,049,150
Net income
-53.88b
L
420,844,53014,677,404,77032,889,711,960355,139,277,000122,451,949,93022,317,719,237-53,881,198,900
CFO
-128.02b
L
14,902,518,69035,972,525,190120,223,790,630536,593,687,780-124,958,284,38029,346,360,897-128,019,868,860
Earnings
Aug 11, 2025

Profile

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea.
IPO date
Mar 18, 2021
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
267,545,049
-27.59%
369,505,556
-19.10%
456,725,871
-50.84%
Cost of revenue
348,820,259
338,772,125
302,391,700
Unusual Expense (Income)
NOPBT
(81,275,210)
30,733,431
154,334,171
NOPBT Margin
8.32%
33.79%
Operating Taxes
(38,989,758)
(14,990,492)
19,281,233
Tax Rate
12.49%
NOPAT
(42,285,452)
45,723,923
135,052,939
Net income
(53,881,199)
-341.43%
22,317,719
-81.77%
122,451,950
-65.52%
Dividends
Dividend yield
Proceeds from repurchase of equity
75,680,234
397,599
2,617,946
BB yield
-1.95%
-0.01%
-0.05%
Debt
Debt current
6,956,508
8,137,402
95,792,981
Long-term debt
395,339,753
33,009,655
47,320,949
Deferred revenue
51,026,374
Other long-term liabilities
1,710,993
527,842
2,648,749
Net debt
66,074,809
(1,275,723,547)
(87,318,302)
Cash flow
Cash from operating activities
(128,019,869)
29,346,361
(124,958,284)
CAPEX
(164,413,439)
(50,295,489)
(76,489,443)
Cash from investing activities
53,563,803
(45,278,721)
272,646,505
Cash from financing activities
252,479,228
(89,582,616)
(19,867,162)
FCF
(830,895,439)
41,501,495
44,335,516
Balance
Cash
1,158,108,158
1,274,141,241
1,480,805,573
Long term investments
(821,886,706)
42,729,362
(1,250,373,341)
Excess cash
322,844,199
1,298,395,326
207,595,939
Stockholders' equity
758,817,858
543,399,377
581,693,865
Invested Capital
1,925,272,141
1,181,557,309
1,629,875,111
ROIC
3.25%
8.57%
ROCE
1.78%
8.40%
EV
Common stock shares outstanding
76,828
77,014
77,021
Price
50,400.00
-30.00%
72,000.00
-2.04%
73,500.00
-67.33%
Market cap
3,872,118,298
-30.17%
5,544,987,408
-2.05%
5,661,079,736
-67.11%
EV
4,158,080,058
4,269,263,861
5,573,761,433
EBITDA
(32,049,976)
65,498,134
181,570,580
EV/EBITDA
65.18
30.70
Interest
3,684,910
1,398,139
2,460,940
Interest/NOPBT
4.55%
1.59%